We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EQA Program for HbA1c Analyzes Lyophilized Human Blood Monthly

By Labmedica staff writers
Posted on 04 Feb 2008
A new cycle of an external quality assessment (EQA) program checks whether laboratories are obtaining accurate results for glycated hemoglobin (HbA1c) testing.

Laboratories worldwide receive samples that they can analyze as if they were patient samples. Each laboratory's test results are compared to the overall results of the group so that laboratories can assess their performance against others using the same analyzers and reagents.

Introduced by Randox (Crumlin, UK), the new cycle of tests is known as the Randox International Quality Assessment Scheme (RIQAS), and is an international EQA scheme used by 7,000 laboratories worldwide, participating in up to nine programs.

The HbA1c program from RIQAS uses lyophilized human blood, which should be analyzed monthly. The EQA samples range from 4-14%, include a linearity series, and cover clinically important decision levels. Once reconstituted, the EQA samples are stable at 2-8 °C for three months and can be used for internal quality control purposes. Participants will receive additional added-value samples during the course of the 12-month cycle.

Comprehensive reports compare participant performance to the overall results of all laboratories using the same instrument and method. Participants register as International Federation of Clinical Chemistry (IFCC) and laboratory medicine-aligned, Diabetes Control and Complications Trial/National Glycohemoglobin Standardization Program (DCCT/NGSP)-aligned, or non-aligned. RIQAS reports are sent by e-transfer within two days of the final date for submission of results or posted within three days of the final date.

HbA1c is used to evaluate diabetics' average blood glucose levels over the preceding six to eight weeks. Elevated HbA1c levels are associated with an increased risk of diabetes complications. Different methods of determining HbA1c can produce varying laboratory results, illustrating the importance of EQA in HbA1c measurement. EQA plays a vital role in the harmonization of HbA1c results worldwide.


Related Links:
Randox

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Clinical Chemistry System
P780

Latest Clinical Chem. News

Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
04 Feb 2008  |   Clinical Chem.

Compact Raman Imaging System Detects Subtle Tumor Signals
04 Feb 2008  |   Clinical Chem.

Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
04 Feb 2008  |   Clinical Chem.